ArticleFrontiers in oncology2026
Case Report: Clinicopathological features of bladder neuroendocrine neoplasm: a retrospective case series of nine cases and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary bladder neuroendocrine neoplasm (BNEN) is an uncommon but clinically aggressive malignancy, and evidence guiding its diagnosis and management remains limited. This retrospective study analyzed nine patients diagnosed with BNEN at a single institution between 2014 and 2024, with pathological classification confirmed by morphology and neuroendocrine immunohistochemical markers. Clinical features, histological subtypes, treatment strategies, and follow-up outcomes were reviewed. Most patients presented with painless gross hematuria and advanced-stage disease. Histologically, the cohort showed marked heterogeneity, including small cell neuroendocrine carcinoma (SCNEC), large cell neuroendocrine carcinoma (LCNEC), paraganglioma (PGL), and mixed neuroendocrine neoplasms. All cases expressed CD56 and synaptophysin, while Ki-67 indices indicated high proliferative activity in most tumors. Despite multimodal treatment, prognosis remained poor. Findings related to immunotherapy were preliminary and should be interpreted with caution. These findings highlight the aggressive and heterogeneous nature of BNEN and support individualized multimodal management, with further studies needed to clarify the role of immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.